Home›Trial›NCT05219500
🔬NCT05219500Phase 2ACTIVE NOT RECRUITING

Targeted Alpha Therapy With 225Actinium-Prostate Specific Membrane Antigen (PSMA)-I&T of Castration-resISTant Prostate Cancer (TATCIST).

Study Summary

The treatment regimen will consist of 4 doses of FPI-2265

Conditions
Metastatic Castration Resistant Prostate Cancer
Interventions / Drugs
FPI-2265
View on ClinicalTrials.gov ↗
Sponsor
FUSN
Fusion Pharmaceuticals
Oncology
D40/100
Study Details
Enrollment115 participants
Primary Completion—
Lead SponsorFusion Pharmaceuticals Inc.
Data Retrieved2026-04-11 04:14:16.520082+00:00
Not financial advice. BiotechSigns data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.